Medicenna Therapeutics (MDNA:TSX) Annual Reports & Investor Relations Material

Overview

Medicenna, a clinical stage immunotherapy company, is focusing on developing new versions of IL-2, IL-4, and IL-13 Superkines, and Empowered Cytokines™ (ECs) for cancer treatment. The company's lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for the treatment of rGBM, the most fatal form of brain cancer. It has demonstrated significant efficacy and obtained Fast-Track and Orphan Drug status. Medicenna's potential long-acting IL2 Superkine, MDNA11, is expected to be a best-in-class next-generation IL-2, with superior binding and a preference for cancer-killing effector T cells and NK cells. The drug is set to be ready for clinical trials in 2021.

Frequently Asked Questions

What is Medicenna Therapeutics's ticker?

Medicenna Therapeutics's ticker is MDNA

What exchange is Medicenna Therapeutics traded on?

The company's shares trade on the TSX stock exchange

Where are Medicenna Therapeutics's headquarters?

They are based in Toronto, Ontario

How many employees does Medicenna Therapeutics have?

There are 1-10 employees working at Medicenna Therapeutics

What is Medicenna Therapeutics's website?

It is medicenna.com

What type of sector is Medicenna Therapeutics?

Medicenna Therapeutics is in the Healthcare sector

What type of industry is Medicenna Therapeutics?

Medicenna Therapeutics is in the Biotechnology industry

Who are Medicenna Therapeutics's peers and competitors?

The following five companies are Medicenna Therapeutics's industry peers:

- Alexion Pharmaceuticals

- Sirtex Medical Limited

- INmune Bio

- Futura Medical plc

- PDS Biotechnology